Immunitas: Strategics back $58M B round to push CD161 inhibitor into the clinic

With a $58 million B round in hand from a swath of new investors, Immunitas is aiming to push its first-in-class CD161 inhibitor into the clinic. Preclinical data give the company confidence that hitting the immuno-oncology target could provide monotherapy efficacy with the potential for synergy with existing immunotherapy treatment options.

Led by Agent Capital, Immunitas Therapeutics Inc.’s round attracted 16 investors including five strategic investors: existing backers Evotec SE (Xetra:EVT), Leaps by Bayer, M Ventures and Novartis Venture Fund and new investor Ono Venture Investment. Founding investor Longwood Fund also participated...